| Literature DB >> 29457027 |
Katarzyna Fejfer1, Piotr Buczko2, Marek Niczyporuk3, Jerzy R Ładny4, Hady R Hady4, Małgorzata Knaś5, Danuta Waszkiel1, Anna Klimiuk1, Anna Zalewska1, Mateusz Maciejczyk6.
Abstract
Morbid obesity leads to progressive failure of many human organs and systems; however, the role of oxidative damage to salivary composition is still unknown in the obese patients. In this study, we assessed the effect of bariatric surgery on oxidative damage in nonstimulated (NS) and stimulated (S) whole saliva. The study included 47 subjects with morbid obesity as well as 47 age- and gender-matched healthy volunteers. Oxidative modifications to lipids (4-hydroxynonenal (4-HNE) and 8-isoprostanes (8-isoP)), proteins (advanced oxidation protein products (AOPP) and protein carbonyl groups (PC)), and DNA (8-hydroxy-D-guanosine (8-OHdG)) were analyzed in morbidly obese patients before and after bariatric surgery as well as in the healthy controls. The concentrations of 8-isoP, AOPP, PC, and 8-OHdG were significantly higher in both NS and S of patients with morbid obesity than in the control patients and compared to the results obtained 6 months after bariatric surgery. The levels of oxidative damage markers were also higher in S versus NS of morbidly obese patients. In summary, morbid obesity is associated with oxidative damage to salivary proteins, lipids, and DNA, while bariatric treatment generally lowers the levels of salivary oxidative damage.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29457027 PMCID: PMC5804359 DOI: 10.1155/2017/4923769
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Demographic data, general health, stomatological findings, salivary flow, and protein concentration of the control and morbid obese patients at the baseline and 6 months after bariatric surgery (mean ± standard deviation).
| C ( | O ( | ABS ( | |
|---|---|---|---|
| Male/female | 14/33 | 14/33 | 14/33 |
| Age | 42.80 ± 13.10 | 44.52 ± 10.51 | 45.12 ± 11.11 |
| BMI (kg/m2) | 20.61 ± 2.31 | 47.10 ± 0.81 | 22.30 ± 3.4 |
| TC (mg/dL) | 147.51 ± 12.8 | 210.70 ± 10.05 | 160.3 ± 11.10 |
| LDL (mg/dL) | 105.70 ± 25.30 | 180.40 ± 15.81 | 119.30 ± 24.11 |
| HDL (mg/dL) | 43.23 ± 2.15 | 29.31 ± 1.12 | 38.23 ± 2.10 |
| DMFT | 20.50 ± 7 | 18.50 ± 9 | 18.50 ± 9 |
| SBI | 0.84 ± 0.10 | 0.9 ± 0.10 | 0.9 ± 0.10 |
| CAL (mm) | 2.7 ± 0.3 | 2.8 ± 0.5 | 2.8 ± 0.5 |
| PPD (mm) | 2.5 ± 1.1 | 2.7 ± 0.5 | 2.7 ± 0.5 |
| NS (mL/min) | 0.41 ± 0.10 | 0.28 ± 0.04 | 0.39 ± 0.17 |
| S (mL/min) | 1.21 ± 0.10 | 0.74 ± 0.20 | 0.76 ± 0.21 |
| TP (NS) (mg/mL) | 0.84 ± 0.01 | 0.64 ± 0.02 | 0.80 ± 0.05 |
| TP (S) (mg/mL) | 1.04 ± 0.25 | 0.75 ± 0.04 | 0.97 ± 0.22 |
C, control; O, morbid obese patients; ABS, patients after the bariatric surgery; BMI, body mass index; TC, total cholesterol; LDL, low density lipoprotein; HDL, high density lipoprotein; DMFT, decayed, missing, filled teeth; SBI, Sulcus Bleeding Index; CAL, clinical attachment loss; PPD, periodontal pocket depth; NS, unstimulated saliva secretion; S, stimulated saliva secretion; TP, total protein. p < 0.05 C:O, p < 0.05 O:ABS, p < 0.05 ABS:C.
Figure 1Oxidative damage to lipids (a, b), proteins (c, d), and DNA (e) in unstimulated and stimulated saliva of patients with morbid obesity at the baseline and 6 months after bariatric surgery as well as the healthy controls. C, control; O, morbid obese patients; ABS, patients after the bariatric surgery; NS, unstimulated whole saliva; S, stimulated whole saliva; 4-HNE protein adducts, 4-hydroxynonenal protein adducts; 8-isoP, 8-isoprostanes; AOPP, advanced oxidation protein products; PC, protein carbonyl groups, 8-OHdG, 8-hydroxyguanosine.
Comparison of oxidative damage products in unstimulated and stimulated saliva of patients with morbid obesity before and after bariatric surgery as well as healthy controls.
| C | O | ABS | ||||
|---|---|---|---|---|---|---|
| NS | S | NS | S | NS | S | |
| 4-HNE | 34.62 ± 8.80 | 49.72 ± 8.34 | 39.49 ± 6.92 | 66.17 ± 15.38 | 34.16 ± 7.94 | 52.22 ± 9.85 |
|
|
|
| ||||
| 8-isoP | 4.65 ± 1.71 | 3.30 ± 0.90 | 14.76 ± 5.41 | 13.05 ± 3.14 | 12.80 ± 4.74 | 10.63 ± 2.12 |
|
|
|
| ||||
| AOPP | 2.07 ± 1.59 | 1.16 ± 0.69 | 7.80 ± 11.37 | 6.45 ± 13.07 | 2.28 ± 1.06 | 1.56 ± 0.75 |
|
|
|
| ||||
| PC | 253.31 ± 103.25 | 282.76 ± 185.58 | 1579.51 ± 403.26 | 1164.21 ± 454.74 | 314.07 ± 104.20 | 398.32 ± 100.54 |
|
|
|
| ||||
| 8-OHdG | 0.43 ± 0.19 | 0.40 ± 0.16 | 1.14 ± 0.83 | 1.77 ± 1.34 | 0.47 ± 0.22 | 0.63 ± 0.18 |
|
|
|
| ||||
C, control; O, morbid obese patients; ABS, patients after the bariatric surgery; NS, unstimulated whole saliva; S, stimulated whole saliva; 4-HNE protein adducts; 4-hydroxynonenal protein adducts; 8-isoP, 8-isoprostanes; AOPP, advanced oxidation protein products; PC, protein carbonyl groups; 8-OHdG, 8-hydroxy-D-guanosine.